1. Home
  2. MRBK vs PLRX Comparison

MRBK vs PLRX Comparison

Compare MRBK & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRBK
  • PLRX
  • Stock Information
  • Founded
  • MRBK 2004
  • PLRX 2015
  • Country
  • MRBK United States
  • PLRX United States
  • Employees
  • MRBK N/A
  • PLRX N/A
  • Industry
  • MRBK Major Banks
  • PLRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRBK Finance
  • PLRX Health Care
  • Exchange
  • MRBK Nasdaq
  • PLRX Nasdaq
  • Market Cap
  • MRBK N/A
  • PLRX 90.9M
  • IPO Year
  • MRBK 2017
  • PLRX 2020
  • Fundamental
  • Price
  • MRBK $13.60
  • PLRX $1.46
  • Analyst Decision
  • MRBK Buy
  • PLRX Hold
  • Analyst Count
  • MRBK 2
  • PLRX 10
  • Target Price
  • MRBK $17.00
  • PLRX $9.79
  • AVG Volume (30 Days)
  • MRBK 57.4K
  • PLRX 744.6K
  • Earning Date
  • MRBK 04-25-2025
  • PLRX 05-20-2025
  • Dividend Yield
  • MRBK 3.67%
  • PLRX N/A
  • EPS Growth
  • MRBK 33.85
  • PLRX N/A
  • EPS
  • MRBK 1.42
  • PLRX N/A
  • Revenue
  • MRBK $101,096,000.00
  • PLRX N/A
  • Revenue This Year
  • MRBK $22.20
  • PLRX N/A
  • Revenue Next Year
  • MRBK $9.93
  • PLRX N/A
  • P/E Ratio
  • MRBK $9.32
  • PLRX N/A
  • Revenue Growth
  • MRBK 8.82
  • PLRX N/A
  • 52 Week Low
  • MRBK $8.80
  • PLRX $1.10
  • 52 Week High
  • MRBK $17.33
  • PLRX $16.52
  • Technical
  • Relative Strength Index (RSI)
  • MRBK 49.51
  • PLRX 41.55
  • Support Level
  • MRBK $13.11
  • PLRX $1.43
  • Resistance Level
  • MRBK $13.79
  • PLRX $1.72
  • Average True Range (ATR)
  • MRBK 0.56
  • PLRX 0.11
  • MACD
  • MRBK 0.03
  • PLRX 0.05
  • Stochastic Oscillator
  • MRBK 34.63
  • PLRX 27.78

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Share on Social Networks: